Key result
Pazopanib shows potential as an oral alternative for taxane-resistant cutaneous angiosarcoma.
Case Report
May offer an oral option in taxane-resistant cutaneous angiosarcoma; leaves open prospective validation before clinical adoption.
Cutaneous angiosarcoma (AS) is a rare and aggressive neoplasm. The prognosis is one of the worst among malignant skin tumors, since the overall 5-year survival rate is less than 30% [1]. Treatment includes surgical excision, radiation, chemotherapy and biological therapy, although the efficacy of these treatments is limited. Surgical excision with negative margins combined with chemotherapy is the most successful strategy for improving the prospect for survival [2].Pazopanib is an orally bioavailable [...]
No takes yet. Share an insight, caveat, or question.
Fujita et al. (2014) conducted a case report in Taxane-resistant cutaneous angiosarcoma. Pazopanib was evaluated. Pazopanib is presented as an orally bioavailable alternative treatment for taxane-resistant cutaneous angiosarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: